Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Centessa Pharmaceuticals ( (CNTA) ) has provided an update.
Centessa Pharmaceuticals has entered into a loan and security agreement with Oxford Finance LLC, securing up to $200 million in term loans to refinance existing debt and support its operations. The initial $110 million loan was used to repay existing obligations under a previous note purchase agreement, and the new agreement includes covenants limiting certain financial actions and securing the loans with a first priority security interest in the company’s assets.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company primarily works on advancing its orexin agonist program, which includes Phase 2 and Phase 3 clinical trials for its lead orexin asset programs.
YTD Price Performance: 112.94%
Average Trading Volume: 531,497
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.23B
See more insights into CNTA stock on TipRanks’ Stock Analysis page.